Baird Medical Expands into San Francisco, Advancing U.S. Market Growth
Baird Medical (NASDAQ: BDMD) announces expansion into San Francisco as part of its U.S. growth strategy, following its participation in the J.P. Morgan Health Conference. Dr. Terrence K. Trapp, an otolaryngologist, has integrated the company's Microwave Ablation (MWA) system into his practice.
Since receiving FDA 510(k) clearance in November 2023, the company has treated hundreds of U.S. patients with its MWA technology, reporting positive treatment outcomes. Notable adoption includes Dr. Emad Kandil at Tulane University, who has performed over 100 MWA procedures.
The company is focusing on expanding physician education and awareness of MWA technology through collaboration with medical specialists and comprehensive training support.
Baird Medical (NASDAQ: BDMD) annuncia l'espansione a San Francisco come parte della sua strategia di crescita negli Stati Uniti, dopo la sua partecipazione alla conferenza sanitaria J.P. Morgan. Il Dr. Terrence K. Trapp, un otorinolaringoiatra, ha integrato il sistema di Ablazione a Microonde (MWA) della società nella sua pratica.
Dopo aver ricevuto il nulla osta FDA 510(k) nel novembre 2023, l'azienda ha trattato centinaia di pazienti negli Stati Uniti con la sua tecnologia MWA, riportando risultati positivi nel trattamento. L'adozione notevole include il Dr. Emad Kandil presso l'Università di Tulane, che ha eseguito oltre 100 procedure MWA.
L'azienda si sta concentrando sull'espansione della formazione e della consapevolezza dei medici riguardo alla tecnologia MWA attraverso la collaborazione con specialisti medici e un supporto formativo completo.
Baird Medical (NASDAQ: BDMD) anuncia su expansión a San Francisco como parte de su estrategia de crecimiento en EE. UU., tras su participación en la Conferencia de Salud de J.P. Morgan. El Dr. Terrence K. Trapp, un otorrinolaringólogo, ha integrado el sistema de Ablación por Microondas (MWA) de la compañía en su práctica.
Desde que recibió la autorización FDA 510(k) en noviembre de 2023, la empresa ha tratado a cientos de pacientes en EE. UU. con su tecnología MWA, reportando resultados positivos en los tratamientos. Una adopción notable incluye al Dr. Emad Kandil de la Universidad de Tulane, quien ha realizado más de 100 procedimientos MWA.
La empresa se enfoca en expandir la educación y la concienciación de los médicos sobre la tecnología MWA a través de la colaboración con especialistas médicos y un soporte de formación integral.
Baird Medical (NASDAQ: BDMD)는 J.P. Morgan 건강 회의에 참여한 후 미국 성장 전략의 일환으로 샌프란시스코로 확장한다고 발표했습니다. 귀이과 의사인 Terrence K. Trapp 박사는 회사의 마이크로웨이브 절제술 (MWA) 시스템을 그의 진료에 통합했습니다.
2023년 11월 FDA 510(k) 승인을 받은 이후, 이 회사는 MWA 기술을 사용하여 수백 명의 미국 환자를 치료했으며 긍정적인 치료 결과를 보고하고 있습니다. 주목할 만한 채택 사례로는 Tulane 대학의 Emad Kandil 박사가 100건 이상의 MWA 절제를 수행한 사례가 있습니다.
회사는 의료 전문가와의 협력 및 포괄적인 교육 지원을 통해 MWA 기술에 대한 의사의 교육 및 인식을 확장하는 데 집중하고 있습니다.
Baird Medical (NASDAQ: BDMD) annonce son expansion à San Francisco dans le cadre de sa stratégie de croissance aux États-Unis, suite à sa participation à la Conférence de Santé J.P. Morgan. Le Dr. Terrence K. Trapp, un oto-rhino-laryngologiste, a intégré le système d'Ablation par Micro-ondes (MWA) de l'entreprise dans sa pratique.
Depuis l'obtention de l'
L'entreprise se concentre sur l'expansion de l'éducation et de la sensibilisation des médecins à la technologie MWA grâce à la collaboration avec des spécialistes médicaux et un soutien à la formation complet.
Baird Medical (NASDAQ: BDMD) kündigt die Expansion nach San Francisco als Teil seiner Wachstumsstrategie in den USA an, nach der Teilnahme an der J.P. Morgan Gesundheitskonferenz. Dr. Terrence K. Trapp, ein Hals-Nasen-Ohren-Arzt, hat das Microwave Ablation (MWA) System des Unternehmens in seine Praxis integriert.
Seit der Erlangung der FDA 510(k) Zulassung im November 2023 hat das Unternehmen Hunderte von US-Patienten mit seiner MWA-Technologie behandelt und positive Behandlungsergebnisse berichtet. Eine bemerkenswerte Adoption umfasst Dr. Emad Kandil von der Tulane-Universität, der über 100 MWA-Verfahren durchgeführt hat.
Das Unternehmen konzentriert sich darauf, die Ausbildung der Ärzte und das Bewusstsein für die MWA-Technologie durch die Zusammenarbeit mit medizinischen Fachleuten und umfassende Schulungsunterstützung zu erweitern.
- FDA 510(k) clearance received in November 2023
- Successful treatment of hundreds of U.S. patients since FDA clearance
- Notable adoption by key medical professionals, with one physician performing over 100 procedures
- Geographic expansion into San Francisco market
- None.
Insights
Baird Medical's strategic expansion into San Francisco marks a calculated move in the $3.5+ billion global ablation market. The timing of this expansion, following the influential J.P. Morgan Healthcare Conference, suggests deliberate positioning to capitalize on increased investor attention and networking opportunities in the biotech hub.
The adoption metrics are particularly noteworthy - the treatment of hundreds of patients since FDA clearance in November 2023 indicates strong initial market penetration. The engagement of Dr. Kandil, who has performed over 100 MWA procedures, serves as a powerful validation of the technology's clinical utility. High-volume adoption by key opinion leaders typically accelerates broader market acceptance and can influence purchasing decisions at major medical institutions.
The San Francisco expansion is strategically significant for several reasons: 1) It provides access to a large, affluent patient population 2) The region's dense concentration of healthcare facilities offers multiple partnership opportunities 3) Proximity to Silicon Valley could facilitate future technological collaborations and funding opportunities.
For investors, this expansion reflects positive execution of Baird's growth strategy. The company's focus on physician education and clinical support demonstrates a comprehensive commercialization approach, which is important for medical device market penetration. However, the real metric to watch will be the conversion rate of trained physicians to regular users, as this will determine long-term revenue growth potential.
As part of this development, Dr. Terrence K. Trapp, an experienced otolaryngologist, has integrated the Company's MWA system into his practice, suggesting growing interest and recognition of minimally invasive approaches for managing thyroid nodules.
Since receiving FDA 510(k) clearance in November 2023, Baird Medical has treated hundreds of patients in
By collaborating with medical specialists and offering comprehensive training and clinical support, Baird Medical is actively expanding physician education and awareness of MWA technology in the
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.
These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.
Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-expands-into-san-francisco-advancing-us-market-growth-302356850.html
SOURCE BDMD
FAQ
When did Baird Medical (BDMD) receive FDA 510(k) clearance for its MWA technology?
How many MWA procedures has Dr. Kandil performed using BDMD's technology?
What is the latest market expansion announced by BDMD?
How many patients has BDMD treated in the US since FDA clearance?
Which medical conference did BDMD attend before its San Francisco expansion?
